Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab plus intranasal mometasone versus placebo plus intranasal mometasone for bilateral nasal polyposis
NL-OMON43359Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Dupilumab + MFNS with Placebo + MFNS (2 arms). Primary endpoints: Change from baseline in nasal congestion/obstruction severity score at Week 24 and Change from baseline in nasal polyp score at Week 24. Started Jun 2017; status: active, not recruiting.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NL-OMON43359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43359.